Targeted therapies in solid tumors: Monoclonal antibodies and small molecules

Human Antibodies

Volumn 15, Issue 3, 2006, Pages 103-111

  Weiner, Louis M ^a   Borghaei, Hossein ^a,b,c  

^a FOX CHASE CANCER CENTER   (United States)

^b AMGEN INC   (United States)

^c GENENTECH INC   (United States)

Author keywords

Cancer; Monoclonal antibodies; Multikinase inhibitors; Small molecules; Tyrosine kinase inhibitors

Indexed keywords

ANTHRACYCLINE; BEVACIZUMAB; BMS 599626; CARBOPLATIN; CDP 791; CETUXIMAB; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIRUBICIN; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GEMCITABINE; IMATINIB; IMC 11 F 8; IMC 1121 B; IRINOTECAN; MATUZUMAB; MDX 214; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY HUMV833; PACLITAXEL; PANITUMUMAB; PELITINIB; PERTUZUMAB; PROTEIN TYROSINE KINASE INHIBITOR; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN ANTIBODY;

ACNE; ACUTE LYMPHOBLASTIC LEUKEMIA; ANTIBODY RESPONSE; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DIMERIZATION; DRUG APPROVAL; DRUG EFFICACY; DRUG ERUPTION; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DYSPEPSIA; FACE RASH; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL TOXICITY; HEAD AND NECK CANCER; HEART DISEASE; HUMAN; HYPERTENSION; LUNG NON SMALL CELL CANCER; METASTASIS; MONOTHERAPY; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SKIN TOXICITY; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; STOMACH CANCER; THROMBOEMBOLISM; TREATMENT RESPONSE; TUMOR GROWTH; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX CANCER; WOUND HEALING; WOUND HEALING IMPAIRMENT;

EID: 33750256756     PISSN: 10932607     EISSN: None     Source Type: Journal    
DOI: 10.3233/hab-2006-15305     Document Type: Review

References (78)

1. E.S. Lander, L.M. Linton, B. Birren et al., Initial sequencing and analysis of the human genome, Nature 409 (2001), 860-921.
2. J.C. Venter, M.D. Adams, E.W. Myers et al., The sequence of the human genome, Science 291 (2001), 1304-1351.
3. Y. Yarden and M.X. Sliwkowski, Untangling the ErbB signalling network, Nat Rev Mol Cell Biol 2 (2001), 127-137.
4. Alroy, Y. Yarden, The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions, FEBS Lett 410 (1997), 83-86.
5. G. Vlahovic and J. Crawford, Activation of tyrosine kinases in cancer, Oncologist 8 (2003), 531-538.
6. S.K. Pal and M. Pegram, Epidermal growth factor receptor and signal transduction: potential targets for anti-cancer therapy, Anti-Cancer Drugs 16 (2005), 483-494.
7. J.A. Meyerhardt and C.S. Fuchs, Epidermal growth factor receptor inhibitors and colorectal cancer, Oncology (Huntington) 18 (2004), 35-38.
8. T.P. Garrett, N.M. McKern, M. Lou et al., The crystal structure of a truncated ErbB 2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors, Mol Cell 11 (2003), 495-505.
9. H.S. Cho, K. Mason, K.X. Ramyar et al., Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab, Nature 421 (2003), 756-760.
10. P.M. Guy, J.V. Platko, L.C. Cantley, R.A. Cerione and K.L. Carraway III, Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity, Proc Natl Acad Sci USA 91 (1994), 8132-8136.
11. L.B. Saltz, N.J. Meropol, P.J. Loehrer Sr, M.N. Needle, J. Kopit and R.J. Mayer, Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor, J Clin Oncol 22 (2004), 1201-1208.
12. D. Cunningham, Y. Humblet, S. Siena et al., Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer, N Engl J Med 351 (2004), 337-345.
13. H.Q. Xiong, A. Rosenberg, A. LoBuglio et al., Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial, J Clin Oncol 22 (2004), 2610-2616.
14. J. Baselga, J.M. Trigo, J. Bourhis et al., Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck, J Clin Oncol 23 (2005), 5568-5577.
15. R.S. Herbst, M. Arquette, D.M. Shin et al., Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck, J Clin Oncol 23 (2005), 5578-5587.
16. Erbitux® (cetuximab) Prescribing Information, ImClone Systems Incorporated and Bristol-Myers Squibb Company, 2005.
17. P. Tyagi, Recent results and ongoing trials with panitumumab (ABX-EGF), a fully human anti-epidermal growth factor receptor antibody, in metastatic colorectal cancer, Clin Colorectal Cancer 5 (2005), 21-23.
18. L. Pertovaara, A. Kaipainen, T. Mustonen et al., Vascular endothelial growth factor is induced in response to transforming growth factor-beta in fibroblastic and epithelial cells, J Biol Chem 269 (1994), 6271-6274.
19. J.R. Hecht, A. Patnaik, I. Malik et al., ABX-EGF monotherapy in patients (pts) with metastatic colorectal cancer (mCRC): an updated analysis, J Clin Oncol 22 (2004), 3511.
20. J. Berlin, I. Malik, J. Picus et al., Panitumumab therapy with irinotecan, 5-fluorouracil, and leucovorin (IFL) in patients (pts) with metastatic colorectal cancer (mCRC), Ann Oncol 15 (2004).
21. J. Berlin, J. Posey, S. Tchekmedyian et al., First line therapy of panitumumab, a fully human antibody, in combination with FOLFIRI for the treatment (txt) of metastatic colorectal cancer (mCRC), Eur J Cancer Suppl 3 (2005), 185.
22. Amgen Press Release, Panitumumab Significantly Improves Progression-Free Survival in Phase 3 Randomized Metastatic Colorectal Cancer Study, First EGFr Inhibitor to Demonstrate Improvement in Progression-Free Survival as Monotherapy for Metastatic Colorectal Cancer, Available at: http://www.amgen.com/media/ media_pr_detail.jsp?releaseID=777851, Accessed November 14, 2005.
23. J. Crawford, P. Swanson, D. Prager et al., Panitumumab, a fully human antibody, combined with paclitaxel and carboplatin versus paclitaxel and carboplatin alone for first line advanced non-small cell lung cancer (NSCLC): a primary analysis, European Journal of Cancer Supplements 3 (2005), 324.
24. E.K. Rowinsky, G.H. Schwartz, J.A. Gollob et al., Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer, J Clin Oncol 22 (2004), 3003-3015.
25. U. Vanhoefer, M. Tewes, F. Rojo et al., Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor, J Clin Oncol 22 (2004), 175-184.
26. L.A. Sorbera, Matummab - solid tumor therapy humanized anti-EGFR monoclonal antibody, Drugs of the Future 30 (2005).
27. D.J. Slamon, B. Leyland-Jones, S. Shak et al., Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2, N Engl J Med 344 (2001), 783-792.
28. W. Eiermann, Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer: pivotal trial data, Ann Oncol 12(suppl 1) (2001), S57-S62.
29. M. Marty, F. Cognetti, D. Maraninchi et al., Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group, J Clin Oncol 23 (2005), 4265-4274.
30. Y. Nieto, J.J. Vredenburgh, E.J. Shpall et al., Phase II feasibility and pharmacokinetic study of concurrent administration of trastuzumab and high-dose chemotherapy in advanced HER2+ breast cancer, Clin Cancer Res 10 (2004), 7136-7143.
31. A.U. Buzdar, N.K. Ibrahim, D. Francis et al., Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer, J Clin Oncol 23 (2005), 3676-3685.
32. M.J. Piccart-Gebhart, M. Procter, B. Leyland-Jones et al., Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer, N Engl J Med 353 (2005), 1659-1672.
33. P.N. Lara Jr., K.G. Chee, J. Longmate et al., Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial, Cancer 100 (2004), 2125-2131.
34. R.K. Ramanathan, J.J. Hwang, W.C. Zamboni et al., Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy: a phase II trial, Cancer Invest 22 (2004), 858-865.
35. U. Gatzemeier, G. Groth, C. Butts et al., Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer, Ann Oncol 15 (2004), 19-27.
36. C.W. Adams, D.E. Allison, K. Flagella et al., Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab, Cancer Immunol Immunother 55 (2006), 717-727.
37. D.B. Agus, R.W. Akita, W.D. Fox et al., Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth, Cancer Cell 2 (2002), 127-137.
38. D.B. Agus, M.S. Gordon, C. Taylor et al., Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer, J Clin Oncol 23 (2005), 2534-2543.
39. P. Nagy, E. Friedlander, M. Tanner et al., Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line, Cancer Res 65 (2005), 473-482.
40. G. McMahon, VEGF receptor signaling in tumor angiogenesis, Oncologist 5(suppl 1) (2000), 3-10.
41. A.F. List, Vascular endothelial growth factor signaling pathway as an emerging target in hematologic malignancies, Oncologist 6(suppl 5) (2001), 24-31.
42. J.C. Lee, N.H. Chow, S.T. Wang and S.M. Huang, Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients, Eur J Cancer 36 (2000), 748-753.
43. T. Tokunaga, Y. Oshika, Y. Abe et al, Vascular endothelial growth factor (VEGF) mRNA isoform expression pattern is correlated with liver metastasis and poor prognosis in colon cancer, Br J Cancer 77 (1998), 998-1002.
44. B.F. El Rayes and P.M. LoRusso, Targeting the epidermal growth factor receptor, Br J Cancer 91 (2004), 418-424.
45. M. Toi, S. Hoshina, T. Takayanagi and T. Tominaga, Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer, Jpn J Cancer Res 85 (1994), 1045-1049.
46. K.J. Kim, B. Li, J. Winer et al., Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo, Nature 362 (1993), 841-844.
47. B. Millauer, L.K. Shawver, K.H. Plate, W. Risau and A. Ullrich, Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant, Nature 367 (1994), 576-579.
48. H. Hurwitz, L. Fehrenbacher, W. Novotny et al., Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer, N Engl J Med 350 (2004), 2335-2342.
49. F.F. Kabbinavar, J. Hambleton, R.D. Mass, H.I. Hurwitz, E. Bergsland and S. Sarkar, Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer, J Clin Oncol 23 (2005), 3706-3712.
50. A.B. Sandler, R. Gray, J. Brahmer et al., Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): an Eastern Cooperative Oncology Group (ECOG) Trial - E4599, J Clin Oncol 23 (2005), LBA4.
51. K.D. Miller, L.I. Chap, F.A. Holmes et al., Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer, J Clin Oncol 23 (2005), 792-799.
52. National Cancer Institute. Bevacizumab combined with chemotherapy improves progression-free survival for patients with advanced breast cancer. Available at: http://www.cancer.gov/newscenter/pressreleases/AvastinBreast. Accessed April 14, 2005.
53. F.A. Scappaticci, L. Fehrenbacher, T. Cartwright et al., Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab, J Surg Oncol 91 (2005), 173-180.
54. G.C. Jayson, C. Mulatero, M. Ranson et al., Phase I investigation of recombinant anti-human vascular endothelial growth factor antibody in patients with advanced cancer, Eur J Cancer 41 (2005), 555-563.
55. Gefitinib (Iressa®) Prescribing Information, AstraZeneca UK Ltd, 2005.
56. M.S. Tsao, A. Sakurada, J.C. Cutz et al., Erlotinib in lung cancer - molecular and clinical predictors of outcome, N Engl J Med 353 (2005), 133-144.
57. F. Blackhall, M. Ranson and N. Thatcher, What next for gefitinib in patients with lung cancer? Lancet Oncol 7 (2006), 499-507.
58. R. Peréz-Soler, A. Chachoua, M. Huberman et al., A phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy, in patients (PTS) with advanced, EGPR-expressing non-small cell lung cancer (NSCLC). Presented at: Annual Meeting of the American Society for Clinical Oncology; May 12-14, 2001; San Francisco, Calif. Abstract 1235.
59. F.A. Shepherd, P.J. Rodrigues, T. Ciuleanu et al., Erlotinib in previously treated non-small-cell lung cancer, N Engl J Med 353 (2005), 123-132.
60. R.S. Herbst, D. Prager, R. Hermann et al., TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer, J Clin Oncol 23 (2005), 5892-5899.
61. U. Gatzemeier, A. Pluzanska, A. Szczesna et al., Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC). Presented at: Annual Meeting of the American Society of Clinical Oncology; June 5-8, 2004; New Orleans, La. Abstract 7010.
62. R. Buchdunger, C.L. Cioffi, N. Law et al., Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors, J Pharmacol Exp Ther 295 (2000), 139-145.
63. K. Okuda, R. Weisberg, D.G. Gilliland and J.D. Griffin, ARG tyrosine kinase activity is inhibited by STI571, Blood 97 (2001), 2440-2448.
64. Gleevec® (imatinib mesylate) Prescribing Information, Novartis Pharmaceuticals, 2005.
65. Erbitux® (cetuximab) Prescribing Information, ImClone Systems Incorporated and Bristol-Myers Squibb Company, 2005.
66. K.J. Busam, P. Capodieci, R. Motzer, T. Kiehn, D. Phelan and A.C. Halpern, Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225, Br J Dermatol 144 (2001), 1169-1176.
67. R. Tan-Chiu, G. Yothers, R. Romond et al., Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31, J Clin Oncol 23 (2005), 7811-7819.
68. H. Ueda, A. Oikawa, A. Nakamura, F. Terasawa, K. Kawagishi and T. Moriizumi, Neuregulin receptor ErbB2 localization at T-tubule in cardiac and skeletal muscle, J Histochem Cytochem 53 (2005), 87-91.
69. Negro, B.K. Brar and K.F. Lee, Essential roles of Her2/erbB2 in cardiac development and function. Recent Prog Horm Res 59 (2004), 1-12.
70. M.H. Cohen, G.A. Williams, R. Sridhara et al., United States Food and Drug Administration drug approval summary: Gefitinib (ZD1839; Iressa) tablets, Clin Cancer Res 10 (2004), 1212-1218.
71. B. Peng, P. Lloyd and H. Schran, Clinical pharmacokinetics of imatinib, Clin Pharmacokinet 44 (2005), 879-894.
72. S. Onoda, H. Mitsufuji, N. Yanase et al., Drug interaction between gefitinib and warfarin, Jpn J Clin Oncol 35 (2005), 478-482.
73. H.C. Swaisland, R.P. Smith, A. Laight et al., Single-dose clinical pharmacokinetic studies of gefitinib, Clin Pharmacokinet 44 (2005), 1165-1177.
74. K. Nakagawa, T. Tamura, S. Negoro et al., Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors, Ann Oncol 14 (2003), 922-930.
75. S. Kobayashi, T.J. Boggon, T. Dayaram et al., EGFR mutation and resistance of non-small-cell lung cancer to gefitinib, N Engl J Med 352 (2005), 786-792.
76. M.E. Gorre, M. Mohammed, K. Ellwood et al., Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification, Science 293 (2001), 876-880.
77. E. Tamborini, L. Bonadiman, A. Greco et al., A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient, Gastroenterology 127 (2004), 294-299.
78. T.A. Carter, L.M. Wodicka, N.P. Shah et al., Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases, Proc Natl Acad Sci USA 102 (2005), 11011-11016.